Compare · Head-to-head
Epitalon vs MOTS-c.
Evidence, risk, regulatory flags, cost, and vendor coverage compared side by side. We don’t sell peptides — we help you choose between them.
Which should you research first?
Start with MOTS-c, then use the table to confirm fit.
MOTS-c is the cleaner first read based on the current evidence, risk, and regulatory data stored for this pair. The right answer can still change if your goal, sport testing status, vendor constraints, or monitoring tolerance makes the other option a better fit.
Comparison next step
Personalize this head-to-head.
Take the quiz before converting a comparison into a compound, vendor, or protocol decision.
01· Subject
Epitalon
Pineal tetrapeptide discussed in aging literature for melatonin/circadian and telomerase pathways. Evidence gaps significant.
01 · At a glance
| Decision factor | Epitalon | MOTS-c |
|---|---|---|
| Primary fit | longevity & anti-aging and sleep & relaxation comparisons | fat loss & metabolism and longevity & anti-aging comparisons |
| Evidence | Tier C-D | Tier C |
| Risk | high | high |
| Experience level | advanced | advanced |
| Budget tier | mid | premium |
| Administration route | subcutaneous, intramuscular, intranasal | subcutaneous |
02 · Use case & timing
| Decision factor | Epitalon | MOTS-c |
|---|---|---|
| Goal fit | Longevity & Anti-Aging, Sleep & Relaxation | Fat Loss & Metabolism, Longevity & Anti-Aging |
| What users compare it for | Longevity/circadian claims; telomerase association not established as fact. | Preclinical: improved insulin sensitivity, metabolic regulation, exercise performance in mice. |
| Onset timeline | Often marketed as weeks-long courses; treat as hypothesis. | Metabolic endpoints assessed over days to weeks in mice; exercise performance improvements after ~10 days. |
| Main tradeoff | Potential upside comes with much more safety and screening caution than lower-risk alternatives. | Potential upside comes with much more safety and screening caution than lower-risk alternatives. |
03 · Safety & restrictions
| Decision factor | Epitalon | MOTS-c |
|---|---|---|
| Adverse effects | Sparse modern safety datasets; high uncertainty. | FDA: no identified human exposure data; significant immunogenicity/characterization risks. |
| Contraindications | No established data. | No human data. |
| Interaction notes | Unknown. | Unknown. |
| Regulatory status | Not approved | Not approved |
| FDA flag | FDA status unclear | FDA compounding caution |
| WADA status | Not listed | Status unclear |
04 · Age & monitoring
| Decision factor | Epitalon | MOTS-c |
|---|---|---|
| Supported age ranges | 35-44, 45-54, 55-64, 65+ | No age guidance yet |
| Life-stage note | Usually discussed in older-adult longevity and sleep-maintenance contexts, not younger performance use. | Not yet documented |
| Monitoring burden | Not specified | Not specified |
| Follow-up cadence | Not yet documented | Not yet documented |
05 · Cost & sourcing
| Decision factor | Epitalon | MOTS-c |
|---|---|---|
| Typical cycle cost | $59.98 | €33.02 |
| Estimated monthly cost | $79.97 | €33.02 |
| Cost confidence | High confidence | High confidence |
06 · Before you buy
| Decision factor | Epitalon | MOTS-c |
|---|---|---|
| Tracked vendor listings | 3 listings | 3 listings |
| Sourcing note | Tracked product pages exist, but naming differences mean the listing needs an extra read before purchase. | Product format varies by listing, so double-check route, concentration, and presentation. |
| Stack-friendly? | Usually stack-friendly | Usually stack-friendly |
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Still deciding
Get a plan tailored to you.
The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.